Weight Loss Drug

More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions. Leaders from major multinationals, including Apple Inc. (NASDAQ:AAPL) and Eli Lilly and Co. (NYSE:LLY), emphasized...

Novo Nordisk AS (NYSE:NVO) and Hims & Hers Health Inc. (NYSE:HIMS) have reportedly ended their public feud, with the drugmaker deciding to sell its weight-loss drug on the telehealth platform. The announcement regarding the new partnership is expected as soon as Monday, Bloomberg reported on...

Novo Nordisk A/S (NYSE:NVO) has lost more than half its value from its peak. NVO stock is down 58% over the past year and more than 40% in just the past month, collapsing from a 52-week high of $91.90 to near $38. But beneath the selloff, something unusual has emerged. Novo Nordisk is no longer...

Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed to delay generic competition. • What’s ahead for NVO stock? The class action complaint, filed in the U.S. District Court,...

Novo Nordisk A/S' (NYSE:NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge. For context, Eli Lilly And Co's (NYSE:LLY) Zepbound hit about...

Stanley Druckenmiller's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionaire investor's family office took a fresh position in VKTX during the second quarter, buying roughly...

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches....

Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals. The firm’s shares...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...

Hims & Hers Health Inc. (NYSE:HIMS) is suddenly looking like the hottest prescription in town – up 220% in the past year and turning heads with a bold new partnership that might just reshape digital healthcare. The company announced a long-term collaboration with pharmaceutical...

Novo Nordisk A/S (NYSE:NVO) has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons. Shares have plunged 44.14% over the past year, 17.4% year-to-date, and 19.27% in the last month. The Novo Nordisk stock fell to a fresh 52-week low of $72.15 — a...

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows. What Happened: A post from Musk on Christmas shared his latest take on...

Novo Nordisk A/S (NYSE:NVO) is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data. While the headlines point to a new trial result that failed to meet expectations, the technical analysis reveals a deeper, more concerning picture...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3). Once-weekly, subcutaneous...

Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic. These new drugs, expected to hit the market by 2029, aim to surpass current efficacy...